← Leaderboards
Rosalie C Sears
Duke University
$14,758,631
Attributed
$24,534,291
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,822,521 · 12
By mechanism
U54$12,459,451 · 2
R01$11,015,861 · 4
U01$10,260,582 · 3
K01$700,113 · 1
R21$369,514 · 1
R13$17,000 · 1
Top collaborators
- Emek Demir11 shared
- Mushui Dai10 shared
- Jonathan Brody9 shared
- Claire J Tomlin7 shared
- Joe W. Gray6 shared
- Lisa M Coussens5 shared
- Gregory A Cote3 shared
- Alexander Savio Ramos Guimaraes3 shared
Most similar at Duke University
Same institution · by research overlap
- Jian Jin$14,335,932
- Michael C Fitzgerald$8,416,267
- Hannah Lynn Thrash$45,707
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMolecularIn VivoResponseTumorCellsIn VitroOncogenicComplexPathway InteractionsMediatingProteinsRegulationCancer CellMutationPhosphorylationThreonineLinkMouse ModelC-Myc GenesTumorigenesisEventAffectCancer Cell Line
Grant awards (68)
An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individuals$4,014,885
U01 · FY2025 · CA · contact PI
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs$766,920
U01 · FY2025 · CA · contact PI
An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individuals$1,035,138
U01 · FY2024 · CA · contact PI
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs$728,573
U01 · FY2024 · CA · contact PI
DeSUMOylation regulation of c-Myc$360,701
R01 · FY2024 · CA · contact PI
Protein Phosphatases$17,000
R13 · FY2024 · CA · contact PI
Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs$766,920
U01 · FY2023 · CA · contact PI
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$546,688
U01 · FY2023 · CA · contact PI
DeSUMOylation regulation of c-Myc$372,091
R01 · FY2023 · CA · contact PI
Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers$158,826
R21 · FY2023 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$547,032
U01 · FY2022 · CA · contact PI
DeSUMOylation regulation of c-Myc$386,742
R01 · FY2022 · CA · contact PI
Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers$210,688
R21 · FY2022 · CA
Measuring, Modeling and Controlling Heterogeneity$1,851,265
U54 · FY2021 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$714,330
U01 · FY2021 · CA · contact PI
Therapeutic Management of Lineage- and Differentiation-state Plasticity$407,312
U54 · FY2021 · CA · contact PI
DeSUMOylation regulation of c-Myc$394,637
R01 · FY2021 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$2,053,370
U54 · FY2020 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$560,027
U01 · FY2020 · CA · contact PI
Therapeutic Management of Lineage- and Differentiation-state Plasticity$404,624
U54 · FY2020 · CA · contact PI
DeSUMOylation regulation of c-Myc$379,685
R01 · FY2020 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$2,164,435
U54 · FY2019 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens$580,069
U01 · FY2019 · CA · contact PI
Therapeutic Management of Lineage- and Differentiation-state Plasticity$474,391
U54 · FY2019 · CA · contact PI
The Role of post-translational activation of Myc in pancreatic cancer$378,485
R01 · FY2019 · CA · contact PI
Deubiquitination regulation of c-Myc$365,173
R01 · FY2019 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$83,652
U54 · FY2019 · CA
Therapeutic Management of Lineage- and Differentiation-state Plasticity$13,942
U54 · FY2019 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$2,191,539
U54 · FY2018 · CA
Therapeutic Management of Lineage- and Differentiation-state Plasticity$465,021
U54 · FY2018 · CA · contact PI
The Role of post-translational activation of Myc in pancreatic cancer$390,191
R01 · FY2018 · CA · contact PI
Deubiquitination regulation of c-Myc$376,467
R01 · FY2018 · CA · contact PI
The Role of post-translational activation of Myc in pancreatic cancer$100,339
R01 · FY2018 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$66,990
U54 · FY2018 · CA
Measuring, Modeling and Controlling Heterogeneity$1,876,979
U54 · FY2017 · CA
Therapeutic Management of Lineage- and Differentiation-state Plasticity$405,931
U54 · FY2017 · CA · contact PI
The Role of post-translational activation of Myc in pancreatic cancer$390,191
R01 · FY2017 · CA · contact PI
Deubiquitination regulation of c-Myc$376,467
R01 · FY2017 · CA · contact PI
The Role of post-translational activation of Myc in pancreatic cancer$392,748
R01 · FY2016 · CA · contact PI
Deubiquitination regulation of c-Myc$383,331
R01 · FY2016 · CA · contact PI
Deubiquitination regulation of c-Myc$395,640
R01 · FY2015 · CA · contact PI
The Role of post-translational activation of Myc in pancreatic cancer$392,748
R01 · FY2015 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$333,224
R01 · FY2014 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$322,918
R01 · FY2013 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$343,530
R01 · FY2012 · CA · contact PI
c-Myc Phosphorylation Sites Regulate Its Apoptotic and Tumorigenic Potential$305,016
R01 · FY2012 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$343,530
R01 · FY2011 · CA · contact PI
c-Myc Phosphorylation Sites Regulate Its Apoptotic and Tumorigenic Potential$305,016
R01 · FY2011 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$354,155
R01 · FY2010 · CA · contact PI
c-Myc Phosphorylation Sites Regulate Its Apoptotic and Tumorigenic Potential$314,449
R01 · FY2010 · CA · contact PI
c-Myc Phosphorylation Sites Regulate Its Apoptotic and Tumorigenic Potential$314,449
R01 · FY2009 · CA · contact PI
c-Myc Phosphorylation Sites Regulate Its Apoptotic and Tumorigenic Potential$314,449
R01 · FY2008 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$306,921
R01 · FY2007 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$55,167
R01 · FY2007 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$375,216
R01 · FY2006 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$53,686
R01 · FY2006 · CA · contact PI
Cellular Mechanisms Controlling Myc Protein Stability$424,511
R01 · FY2005 · CA
Integration of Ras, Myc and E2F Signaling Pathways$149,761
K01 · FY2005 · CA
Cellular Mechanisms Controlling Myc Protein Stability$52,097
R01 · FY2005 · CA
Cellular Mechanisms Controlling Myc Protein Stability$40,466
R01 · FY2005 · CA
Cellular Mechanisms Controlling Myc Protein Stability$28,244
R01 · FY2005 · CA
Cellular Mechanisms Controlling Myc Protein Stability$296,477
R01 · FY2004 · CA
Integration of Ras, Myc and E2F Signaling Pathways$146,972
K01 · FY2004 · CA
Cellular Mechanisms Controlling Myc Protein Stability$296,704
R01 · FY2003 · CA
Integration of Ras, Myc and E2F Signaling Pathways$144,264
K01 · FY2003 · CA
Integration of Ras, Myc and E2F Signaling Pathways$141,634
K01 · FY2002 · CA
Integration of Ras, Myc and E2F Signaling Pathways$43,892
K01 · FY2002 · CA
Integration of Ras, Myc and E2F Signaling Pathways$73,590
K01 · FY2001 · CA